Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...
Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...
(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
After careful consideration and with the assistance of its independent financial and legal advisors, the Board unanimously concluded that the Concentra proposal substantially undervalues the Company.
KLAS Las Vegas on MSN1d
Las Vegas-area prison employee suspected of impairment sent home, crashes and diesA Nevada state employee suspected of being under the influence was sent home from work and then crashed and died, the 8 News ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback